SCHEMBL18838396

SCHEMBL18838396

O=C(NC1CC12CCN(Cc1ccccc1)CC2)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNH2 Q12809 4/20 0.48
▸ MCHR1 Q99705 2/20 0.47
▸ HDAC4 P56524 1/20 0.47
▸ HDAC1 Q13547 1/20 0.47
▸ SLC6A12 P48065 3/20 0.47
▸ DRD4 P21917 1/20 0.47
▸ SLC6A13 Q9NSD5 1/20 0.47
▸ CACNA1I Q9P0X4 1/20 0.46
▸ MAOB P27338 1/20 0.46
▸ SIGMAR1 Q99720 3/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ CHRM2 P08172 1/20 0.46
▸ CHRM3 P20309 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ TMEM97 Q5BJF2 2/20 0.46
▸ MAPK1 P28482 2/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18838376 0.90 KCNH2 (0.60) KCNH2DRD4SIGMAR1KMT2AMEN1
SCHEMBL18838471 0.89 KCNH2 (0.56) KCNH2MCHR1HDAC4HDAC1SLC6A12
SCHEMBL18838407 0.88 KCNH2 (0.53) KCNH2DRD4SIGMAR1KMT2AMEN1
SCHEMBL18860342 0.88 MCHR1 (0.47) KCNH2MCHR1SLC6A12DRD4SLC6A13
SCHEMBL18838401 0.87 KMT2A (0.54) KCNH2MCHR1HDAC4HDAC1SLC6A12
SCHEMBL18838307 0.86 SCN9A (0.42) KCNH2MCHR1CACNA1I
SCHEMBL28678612 0.83 ENPP2 (0.47) HDAC1KMT2AMEN1CYP2C19NPSR1
SCHEMBL18838494 0.83 ENPP2 (0.47) HDAC1KMT2AMEN1CYP2C19NPSR1
SCHEMBL18860226 0.83 ENPP2 (0.47) HDAC1KMT2AMEN1CYP2C19NPSR1
SCHEMBL9566447 0.82 HDAC1 (0.50) KCNH2MCHR1HDAC4HDAC1SLC6A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3340988-B1 ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES AFASCI INC (US) 2025-04-09 — — EP disclosed
CN-108289886-B Ion channel inhibiting compounds, pharmaceutical formulations and uses 安华赛公司 2022-01-28 — — CN disclosed
US-10562857-B2 Ion channel inhibitory compounds, pharmaceutical formulations, and uses AFASCI, INC. (US) 2020-02-18 — — US disclosed
US-10562857-B2 Ion channel inhibitory compounds, pharmaceutical formulations, and uses AFASCI, INC. (US) 2020-02-18 — — US disclosed
US-20180312471-A1 Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses AFASCI, INC. (US) 2018-11-01 — — US disclosed
EP-3340988-A1 ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES Afasci, Inc. (US) 2018-07-04 — — EP disclosed
WO-2017083867-A1 ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES AFASCI, INC. (US) 2017-05-18 — — WO disclosed
WO-2017083867-A1 ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES AFASCI, INC. (US) 2017-05-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562857-B2 Ion channel inhibitory compounds, pharmaceutical formulations, and uses CACNA1I, CACNA1G, CACNA1H KCNH2 55/4885MCHR1 2757/4885HDAC4 1119/4885
US-20180312471-A1 Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses CACNA1I, CACNA1G, CACNA1H KCNH2 55/4885MCHR1 2757/4885HDAC4 1119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback